Pub Date : 2024-01-01DOI: 10.33696/cancerimmunol.6.080
Mehmet A Baysal, Abhijit Chakraborty, Apostolia M Tsimberidou
The emergence of chimeric antigen receptor T cell (CAR-T cell) therapy has revolutionized cancer treatment, particularly for hematologic malignancies. This commentary discusses developments in CAR-T cell therapy, focusing on the molecular mechanisms governing T cell fate and differentiation. Transcriptional and epigenetic factors play a pivotal role in determining the specificity, effectiveness, and durability of CAR-T cell therapy. Understanding these mechanisms is crucial to improve the efficacy and decrease the adverse events associated with CAR-T cell therapies, unlocking the full potential of these approaches. T cell differentiation in CAR-T cell product manufacturing plays an important role in clinical outcomes. A positive correlation exists between the clinical efficacy of CAR-T cell therapy and signatures of memory, whereas a negative correlation has been observed with signatures of effector function or exhaustion. The effectiveness of CAR-T cell products is likely influenced by T-cell frequency and by their ability to proliferate, which is closely linked to early T cell differentiation. The differentiation process involving distinct T memory cell subsets is initiated upon antigen elimination, indicating infection resolution. In chronic infections or cancer, T cells may undergo exhaustion, marked by continuous inhibitory receptor expression, decreased cytokine production, and diminished proliferative capacity. Other cell subsets, such as CD4+ T cells, innate-like T lymphocytes, NKT cells, and cord blood-derived hematopoietic stem cells, offer unique advantages in developing the next-generation CAR-T cell-based therapies. Future research should focus on optimizing T-cell-enhancing approaches and developing strategies to potentially cure patients with hematological diseases and solid tumors.
嵌合抗原受体 T 细胞（CAR-T 细胞）疗法的出现彻底改变了癌症治疗，尤其是血液系统恶性肿瘤的治疗。这篇评论讨论了CAR-T细胞疗法的发展，重点是支配T细胞命运和分化的分子机制。转录和表观遗传因素在决定 CAR-T 细胞疗法的特异性、有效性和持久性方面起着关键作用。了解这些机制对于提高 CAR-T 细胞疗法的疗效、减少不良反应、充分挖掘这些疗法的潜力至关重要。CAR-T 细胞产品生产过程中的 T 细胞分化对临床结果起着重要作用。CAR-T 细胞疗法的临床疗效与记忆特征呈正相关，而与效应器功能或衰竭特征呈负相关。CAR-T 细胞产品的有效性可能受到 T 细胞频率及其增殖能力的影响，而增殖能力与 T 细胞的早期分化密切相关。涉及不同 T 记忆细胞亚群的分化过程是在抗原消除后启动的，这表明感染得到了解决。在慢性感染或癌症中，T 细胞可能会衰竭，表现为持续的抑制性受体表达、细胞因子分泌减少以及增殖能力减弱。其他细胞亚群，如 CD4+ T 细胞、先天性类 T 淋巴细胞、NKT 细胞和脐带血造血干细胞，在开发基于 CAR-T 细胞的下一代疗法方面具有独特的优势。未来的研究重点应放在优化T细胞增强方法和开发可能治愈血液病和实体瘤患者的策略上。
{"title":"Enhancing the Efficacy of CAR-T Cell Therapy: A Comprehensive Exploration of Cellular Strategies and Molecular Dynamics.","authors":"Mehmet A Baysal, Abhijit Chakraborty, Apostolia M Tsimberidou","doi":"10.33696/cancerimmunol.6.080","DOIUrl":"10.33696/cancerimmunol.6.080","url":null,"abstract":"<p><p>The emergence of chimeric antigen receptor T cell (CAR-T cell) therapy has revolutionized cancer treatment, particularly for hematologic malignancies. This commentary discusses developments in CAR-T cell therapy, focusing on the molecular mechanisms governing T cell fate and differentiation. Transcriptional and epigenetic factors play a pivotal role in determining the specificity, effectiveness, and durability of CAR-T cell therapy. Understanding these mechanisms is crucial to improve the efficacy and decrease the adverse events associated with CAR-T cell therapies, unlocking the full potential of these approaches. T cell differentiation in CAR-T cell product manufacturing plays an important role in clinical outcomes. A positive correlation exists between the clinical efficacy of CAR-T cell therapy and signatures of memory, whereas a negative correlation has been observed with signatures of effector function or exhaustion. The effectiveness of CAR-T cell products is likely influenced by T-cell frequency and by their ability to proliferate, which is closely linked to early T cell differentiation. The differentiation process involving distinct T memory cell subsets is initiated upon antigen elimination, indicating infection resolution. In chronic infections or cancer, T cells may undergo exhaustion, marked by continuous inhibitory receptor expression, decreased cytokine production, and diminished proliferative capacity. Other cell subsets, such as CD4<sup>+</sup> T cells, innate-like T lymphocytes, NKT cells, and cord blood-derived hematopoietic stem cells, offer unique advantages in developing the next-generation CAR-T cell-based therapies. Future research should focus on optimizing T-cell-enhancing approaches and developing strategies to potentially cure patients with hematological diseases and solid tumors.</p>","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"6 1","pages":"20-28"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11308461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141908570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.33696/cancerimmunol.6.093
Zaineb Hassouneh, Gang Huang, Nu Zhang, Manjeet Rao, Neelam Mukherjee
{"title":"Commentary: On the Emerging Role of Innate Lymphoid Cells in Bladder Cancer.","authors":"Zaineb Hassouneh, Gang Huang, Nu Zhang, Manjeet Rao, Neelam Mukherjee","doi":"10.33696/cancerimmunol.6.093","DOIUrl":"10.33696/cancerimmunol.6.093","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"6 3","pages":"125-134"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11580033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-28DOI: 10.33696/cancerimmunol.5.076
Khushwant Singh, P. K. Gautam
Head and neck squamous cell carcinoma (HNSCC) are a group of cancers that affect various parts of the head and neck, such as the lip, oral cavity, oropharynx, hypopharynx, and nasopharynx. In India, it accounts for approximately 30–40% of all cancers, while in the United States, it represents around 4% of all cancer cases. HNSCC is a significant contributor to cancer-related deaths globally. While smoking is linked to HNSCC, recent research has confirmed the importance of the human papillomavirus (HPV) in its development. Additionally, HNSCC is characterized by immune deficiencies, where the tumor microenvironment alters immune cell activity to facilitate carcinogenesis. However, researchers have identified novel immunotherapeutic targets for HNSCC, mainly by studying the involvement of inflammatory cells such as neutrophils, eosinophils, and macrophages. Unfortunately, patients with recurring malignancy and distant metastases have limited treatment options, with a prognosis of less than one year. Platinum-based chemotherapy, cetuximab, and other conventional therapies are used to treat recurrent and metastatic HNSCC. The pro and anti-tumor roles of neutrophils in cancer and immunotherapy are explored in this study, with a focus on HNSCC. The primary objective is to increase our understanding of HNSCC biology and immunobiology to uncover viable therapeutic options that are both valid and less cytotoxic.
{"title":"Emulating the Role of Neutrophils in Head and Neck Cancer Microenvironment: Prognostic Role and Therapeutic Strategies","authors":"Khushwant Singh, P. K. Gautam","doi":"10.33696/cancerimmunol.5.076","DOIUrl":"https://doi.org/10.33696/cancerimmunol.5.076","url":null,"abstract":"Head and neck squamous cell carcinoma (HNSCC) are a group of cancers that affect various parts of the head and neck, such as the lip, oral cavity, oropharynx, hypopharynx, and nasopharynx. In India, it accounts for approximately 30–40% of all cancers, while in the United States, it represents around 4% of all cancer cases. HNSCC is a significant contributor to cancer-related deaths globally. While smoking is linked to HNSCC, recent research has confirmed the importance of the human papillomavirus (HPV) in its development. Additionally, HNSCC is characterized by immune deficiencies, where the tumor microenvironment alters immune cell activity to facilitate carcinogenesis. However, researchers have identified novel immunotherapeutic targets for HNSCC, mainly by studying the involvement of inflammatory cells such as neutrophils, eosinophils, and macrophages. Unfortunately, patients with recurring malignancy and distant metastases have limited treatment options, with a prognosis of less than one year. Platinum-based chemotherapy, cetuximab, and other conventional therapies are used to treat recurrent and metastatic HNSCC. The pro and anti-tumor roles of neutrophils in cancer and immunotherapy are explored in this study, with a focus on HNSCC. The primary objective is to increase our understanding of HNSCC biology and immunobiology to uncover viable therapeutic options that are both valid and less cytotoxic.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41455223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-28DOI: 10.33696/cancerimmunol.5.077
L. Cabezón-Gutiérrez, S. Custodio-Cabello, V. Pacheco-Barcia, Magda Palka-Kotlowska, Catalina Saez-Bertrand, Marta Blasco-Guerrero
Background: In advanced non-small-cell lung cancer (NSCLC), second-line treatment with nintedanib plus docetaxel improves survival compared with docetaxel, especially in patients with adenocarcinoma histology who progressed within 9 months after the start of firstline treatment. It is therefore necessary to identify new biomarkers/prognostic factors that select the patients who benefit from this type of treatment. Patients and Methods: In this single-center retrospective study, we included patients treated NSCLC with nintedanib plus docetaxel in the second/third line and analyzed potential prognostic factors, many of them related to the inflammatory environment; PD-L1 expression levels, Lung Immune Prognostic Index (LIPI), derived neutrophil/lymphocytes ratio (dNLR), etc. Results: Among 16 patients included in this analysis, the overall response rate was 12.5%, median progression-free survival was 2 months (95% CI, 1.22-2.78) and median overall survival was 6 months (95% CI, 2.11-9.89). LDH level is the only variable related to the disease control rate (70% in normal versus 0% in elevated LDH). The variables analyzed with prognostic significance were; no brain metastases (HR 0.33, 95% CI 0.14-0.78; p=0.011), less than 3 metastatic sites (HR 0.33, 95% CI 0.14-0.78; p=0.011), the non-use of antiangiogenic drugs in the first line (HR 0.53, 95% CI: 0.29-0.98; p=0.043), the absence of elevated LDH at the start of treatment (HR 0.55, 95% CI: 0.3-1; p=0.051) and the absence of liver metastases (HR 0.55, 95% CI: 0.29-1; p=0.05). Conclusions: In NSCLC patients with less than three metastatic sites, no brain or liver metastases, normal LDH values and not previously treated with antiangiogenic drugs in the first line showed a better prognosis when treated with second/third line with nintedanib plus docetaxel.
{"title":"Prognostic Factors of Nintedanib-docetaxel in Patients with Previously Treated Non-small-cell Lung Cancer","authors":"L. Cabezón-Gutiérrez, S. Custodio-Cabello, V. Pacheco-Barcia, Magda Palka-Kotlowska, Catalina Saez-Bertrand, Marta Blasco-Guerrero","doi":"10.33696/cancerimmunol.5.077","DOIUrl":"https://doi.org/10.33696/cancerimmunol.5.077","url":null,"abstract":"Background: In advanced non-small-cell lung cancer (NSCLC), second-line treatment with nintedanib plus docetaxel improves survival compared with docetaxel, especially in patients with adenocarcinoma histology who progressed within 9 months after the start of firstline treatment. It is therefore necessary to identify new biomarkers/prognostic factors that select the patients who benefit from this type of treatment.\u0000\u0000Patients and Methods: In this single-center retrospective study, we included patients treated NSCLC with nintedanib plus docetaxel in the second/third line and analyzed potential prognostic factors, many of them related to the inflammatory environment; PD-L1 expression levels, Lung Immune Prognostic Index (LIPI), derived neutrophil/lymphocytes ratio (dNLR), etc.\u0000\u0000Results: Among 16 patients included in this analysis, the overall response rate was 12.5%, median progression-free survival was 2 months (95% CI, 1.22-2.78) and median overall survival was 6 months (95% CI, 2.11-9.89). LDH level is the only variable related to the disease control rate (70% in normal versus 0% in elevated LDH). The variables analyzed with prognostic significance were; no brain metastases (HR 0.33, 95% CI 0.14-0.78; p=0.011), less than 3 metastatic sites (HR 0.33, 95% CI 0.14-0.78; p=0.011), the non-use of antiangiogenic drugs in the first line (HR 0.53, 95% CI: 0.29-0.98; p=0.043), the absence of elevated LDH at the start of treatment (HR 0.55, 95% CI: 0.3-1; p=0.051) and the absence of liver metastases (HR 0.55, 95% CI: 0.29-1; p=0.05).\u0000\u0000Conclusions: In NSCLC patients with less than three metastatic sites, no brain or liver metastases, normal LDH values and not previously treated with antiangiogenic drugs in the first line showed a better prognosis when treated with second/third line with nintedanib plus docetaxel.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48719982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-07DOI: 10.33696/cancerimmunol.5.075
Devavrat Tripathi, P. Gupta, S. Kulkarni
Metastasis is the perilous aspect of cancer and is responsible for 90% of deaths due to cancer. It represents an enigmatic and complex biological cascade that is poorly understood. The constant development in cancer research and the advent of new principles in metastasis have discovered some of the molecular keystones like epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) of this cascade. Acknowledgment of the communications between cancer cells and their micro-environment enlightens the biology of metastasis and allows us to understand the mechanism of EMT induction and its role in governing invasion, migration, plasticity, colonization, and therapeutic resistance. EMT is the principal reason behind the cancer cells’ complex behavior, tremendous plasticity, survival, and adoption in a constantly changing environment. Thus, EMT is a perfect driver mechanism to execute metastasis and develop resistance against conventional and targeted therapies. Studies have also discovered the role of EMT in CSCs generation and offered us prospects for evolving more effective treatments to target metastasis and improved patient prognosis. Our primary aim in the present review is to summarize the induction and role of EMT in cancer. This review not only discusses the role of EMT in metastasis but also uncovers the role of EMT in survival, metabolism, and CSCs generation. Further, in this review, we also discuss the strategy to target the EMT for the development of new and effective therapeutics for cancer management.
{"title":"Epithelial Mesenchymal Transition: The Ultimate Driver of Cancer on Difficult Paths","authors":"Devavrat Tripathi, P. Gupta, S. Kulkarni","doi":"10.33696/cancerimmunol.5.075","DOIUrl":"https://doi.org/10.33696/cancerimmunol.5.075","url":null,"abstract":"Metastasis is the perilous aspect of cancer and is responsible for 90% of deaths due to cancer. It represents an enigmatic and complex biological cascade that is poorly understood. The constant development in cancer research and the advent of new principles in metastasis have discovered some of the molecular keystones like epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) of this cascade. Acknowledgment of the communications between cancer cells and their micro-environment enlightens the biology of metastasis and allows us to understand the mechanism of EMT induction and its role in governing invasion, migration, plasticity, colonization, and therapeutic resistance. EMT is the principal reason behind the cancer cells’ complex behavior, tremendous plasticity, survival, and adoption in a constantly changing environment. Thus, EMT is a perfect driver mechanism to execute metastasis and develop resistance against conventional and targeted therapies. Studies have also discovered the role of EMT in CSCs generation and offered us prospects for evolving more effective treatments to target metastasis and improved patient prognosis.\u0000\u0000Our primary aim in the present review is to summarize the induction and role of EMT in cancer. This review not only discusses the role of EMT in metastasis but also uncovers the role of EMT in survival, metabolism, and CSCs generation. Further, in this review, we also discuss the strategy to target the EMT for the development of new and effective therapeutics for cancer management.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42190982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-23DOI: 10.33696/cancerimmunol.5.074
I. Amit, Natalie Levitin, Meital Gadrich, May Ben-Mayor, T. Wyant, Reut Barak, Liron Danielpur, Morya Ifrach, Itzhak Meir, Olga Bluvshtein, Yehezkel Sasson, Sharon Fischman, Guy Nimrod, Michael Zhenin, Yair Fastman, J. Vasselli, Aron Knickerbocker, R. Herbst, Yanay Ofran
Stimulating effector T-cells (Teffs) without inducing regulatory T-cells (Tregs) has been the primary goal of IL-2-based therapies for cancer. Recently, modified IL-2 designed for differential T-cell expansion for the treatment of cancer has failed in the clinic. We propose that treatments based on exogenous administrations of modified IL-2 are inherently undermined by a negative feedback loop, caused by IL-2 secreted endogenously from activated effector T-cells. This endogenous IL-2 secretion subsequentially induces Treg expansion and inhibits the immune response that is essential for cancer clearance. Here, we demonstrate that treatments utilizing exogenous modified IL-2 indeed induce Treg expansion. To circumvent this negative feedback, we computationally designed a novel monoclonal humanized antibody (AU-007) that binds human IL-2 with pM affinity at a predefined epitope and completely blocks IL-2 binding to CD25 that is highly expressed on Tregs, without hindering IL-2 binding to CD122/CD132 dimer receptor expressed over effector cells. This epitope-specific, high-affinity antibody controls endogenous IL-2 and prevents it from expanding Tregs while allowing it to expand Teffs. We show that controlling endogenous IL-2 using AU-007 abrogates the negative feedback loop and replaces it with a positive feedback loop that enhances the expansion of NK cells and Teffs, an effect considered favorable for cancer immunotherapy.
{"title":"Negative Feedback Expansion of Tregs Caused by Endogenous IL-2 Limits the Activity of IL-2-based Therapies","authors":"I. Amit, Natalie Levitin, Meital Gadrich, May Ben-Mayor, T. Wyant, Reut Barak, Liron Danielpur, Morya Ifrach, Itzhak Meir, Olga Bluvshtein, Yehezkel Sasson, Sharon Fischman, Guy Nimrod, Michael Zhenin, Yair Fastman, J. Vasselli, Aron Knickerbocker, R. Herbst, Yanay Ofran","doi":"10.33696/cancerimmunol.5.074","DOIUrl":"https://doi.org/10.33696/cancerimmunol.5.074","url":null,"abstract":"Stimulating effector T-cells (Teffs) without inducing regulatory T-cells (Tregs) has been the primary goal of IL-2-based therapies for cancer. Recently, modified IL-2 designed for differential T-cell expansion for the treatment of cancer has failed in the clinic. We propose that treatments based on exogenous administrations of modified IL-2 are inherently undermined by a negative feedback loop, caused by IL-2 secreted endogenously from activated effector T-cells. This endogenous IL-2 secretion subsequentially induces Treg expansion and inhibits the immune response that is essential for cancer clearance. Here, we demonstrate that treatments utilizing exogenous modified IL-2 indeed induce Treg expansion. To circumvent this negative feedback, we computationally designed a novel monoclonal humanized antibody (AU-007) that binds human IL-2 with pM affinity at a predefined epitope and completely blocks IL-2 binding to CD25 that is highly expressed on Tregs, without hindering IL-2 binding to CD122/CD132 dimer receptor expressed over effector cells. This epitope-specific, high-affinity antibody controls endogenous IL-2 and prevents it from expanding Tregs while allowing it to expand Teffs. We show that controlling endogenous IL-2 using AU-007 abrogates the negative feedback loop and replaces it with a positive feedback loop that enhances the expansion of NK cells and Teffs, an effect considered favorable for cancer immunotherapy.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43784319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-23DOI: 10.33696/cancerimmunol.5.073
Yelin Liang, Yuan Zhang, Xirong Tan, Han Qiao, Jun Ma, Yingqin Li, Na Liu
Accumulating evidence from recent research offers new perspectives on the functions of long non-coding RNAs (lncRNAs) in immunooncology. In addition to modulating the aggressiveness of cancer cells, lncRNAs are essential players in regulating various immune cells and stromal cells, playing a role in reshaping the tumor microenvironment and affecting anti-tumor immunity. The insightful discoveries on the role of lncRNAs in immuno-oncological activities indicate the prognostic value of lncRNA markers. Here, we present an overview of the roles of lncRNAs derived from different cell types in the tumor microenvironment, that is, immune cells, tumor cells, and stromal cells, and summarize their functional characterization and mechanisms in immuno-oncological activities. We also discuss the opportunities and challenges of single-cell-based technologies for analyzing the cellular function of immune-related lncRNAs.
{"title":"Insights from Long Noncoding RNAs into Cancer-immunity Cycle Regulation","authors":"Yelin Liang, Yuan Zhang, Xirong Tan, Han Qiao, Jun Ma, Yingqin Li, Na Liu","doi":"10.33696/cancerimmunol.5.073","DOIUrl":"https://doi.org/10.33696/cancerimmunol.5.073","url":null,"abstract":"Accumulating evidence from recent research offers new perspectives on the functions of long non-coding RNAs (lncRNAs) in immunooncology. In addition to modulating the aggressiveness of cancer cells, lncRNAs are essential players in regulating various immune cells and stromal cells, playing a role in reshaping the tumor microenvironment and affecting anti-tumor immunity. The insightful discoveries on the role of lncRNAs in immuno-oncological activities indicate the prognostic value of lncRNA markers. Here, we present an overview of the roles of lncRNAs derived from different cell types in the tumor microenvironment, that is, immune cells, tumor cells, and stromal cells, and summarize their functional characterization and mechanisms in immuno-oncological activities. We also discuss the opportunities and challenges of single-cell-based technologies for analyzing the cellular function of immune-related lncRNAs.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43063689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-26DOI: 10.33696/cancerimmunol.5.070
S. Dakua, Sagnika Dash, Sagarika Pati, J. Abinahed
{"title":"Role of Liver Navigation in Surgery Planning and the Challenges","authors":"S. Dakua, Sagnika Dash, Sagarika Pati, J. Abinahed","doi":"10.33696/cancerimmunol.5.070","DOIUrl":"https://doi.org/10.33696/cancerimmunol.5.070","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43576908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.33696/cancerimmunol.5.072
Megan Stout, Akshay Thaper, Vivien Xu, Eric A Singer, Biren Saraiya
{"title":"Early Integration of Palliative Care for Patients Receiving Systemic Immunotherapy for Renal Cell Carcinoma.","authors":"Megan Stout, Akshay Thaper, Vivien Xu, Eric A Singer, Biren Saraiya","doi":"10.33696/cancerimmunol.5.072","DOIUrl":"10.33696/cancerimmunol.5.072","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"5 1","pages":"5-12"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9672570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-22DOI: 10.33696/cancerimmunol.4.067
{"title":"Molecular Iodine Misconceptions: A Novel Formulation Approach to Topical Iodine","authors":"","doi":"10.33696/cancerimmunol.4.067","DOIUrl":"https://doi.org/10.33696/cancerimmunol.4.067","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47949465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号